Laser heat treatment for glioblastoma that returns before radiotherapy begins
Tests laser heat therapy in adults whose glioblastoma returns before radiotherapy starts.
Plain-language title generated from the registry record
Registry title: LITT for Ultra-early GBM Recurrence
Key facts
- Where
- Bern, SwitzerlandSee the site
Where in Switzerland
- Dep. of Neurosurgery, Bern University HospitalBern, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT07616986
- Record updated
- 1 June 2026
- Original description
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.Read full original descriptionShow less
Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence
Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.
LITT offers a minimally invasive alternative that may:
* Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.
Inclusion: Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status; ≥18 years of age; CRET; Karnofsky Performance Status (KPS) ≥70; No contra-indication for radio-chemotherapy; Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern; Able to provide informed consent; No contra-indication for LITT; No pregnancy or active breast-feeding; No known coagulopathy independent of medication; No dissemination or multifocal disease; Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.